General
| Peptide: | SMAP-29 |
| Microorganism: | Stenotrophomonas maltophilia |
| Administration: | |
| Stage: | Formation (3-24h) |
| Notes: | Sm109 clinical isolate |
Experimental procedure
| Method | AMP Effect(Biofilm reduction) | Concentration | Notes |
|---|---|---|---|
| Crystal violet assay | > 90% | 0.626 uM | |
| Crystal violet assay | 51 - 90% | 0.313 uM | |
| Crystal violet assay | <= 20 % | 0 uM |
Reference
- A. Pompilio, M. Scocchi, S. Pomponio, F. Guida, A. Di Primio, E. Fiscarelli, R. Gennaro, G. Di Bonaventura Antibacterial and anti-biofilm effects of cathelicidin peptides against pathogens isolated from cystic fibrosis patients
M. Di Luca, G. Maccari, G. Maisetta, G. Batoni BaAMPs: the database of biofilm-active antimicrobial peptides Biofouling 2015; 31(2):193-9.
Please do not hesitate to address comments or questions to: mariagrazia.diluca@nano.cnr.it or gpmaccari@gmail.com